Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Change in Receivables (2020 - 2025)

Journey Medical (DERM) has disclosed Change in Receivables for 6 consecutive years, with $2.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Receivables rose 175.37% year-over-year to $2.4 million, compared with a TTM value of $6.8 million through Sep 2025, up 98.23%, and an annual FY2024 reading of -$4.5 million, up 64.35% over the prior year.
  • Change in Receivables was $2.4 million for Q3 2025 at Journey Medical, up from -$2.8 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $8.0 million in Q1 2022 and bottomed at -$10.4 million in Q2 2023.
  • Average Change in Receivables over 5 years is -$254315.8, with a median of -$83000.0 recorded in 2022.
  • Peak annual rise in Change in Receivables hit 14170.59% in 2023, while the deepest fall reached 10538.55% in 2023.
  • Year by year, Change in Receivables stood at -$8.5 million in 2021, then soared by 99.4% to -$51000.0 in 2022, then skyrocketed by 14170.59% to $7.2 million in 2023, then plummeted by 110.41% to -$747000.0 in 2024, then soared by 423.29% to $2.4 million in 2025.
  • Business Quant data shows Change in Receivables for DERM at $2.4 million in Q3 2025, -$2.8 million in Q2 2025, and $8.0 million in Q1 2025.